Table 3.

Effect of replenishing Qi and activating blood on APP and Aβ_1-42 expression in hippocampal CA1 region of APP/PS1 double transgenic ischemic mice ($\bar{x}±s$)

Group	Dose (mg/kg·d)	Visual field number (n)	APP	Aβ1-42
C57 sham-operated	-	12	1.15±0.5	3.75±1.2
C57 ischemia	-	12	1.46±0.5	8.12±1.0d
APP/PS1 model	-	12	5.53±0.8a	19.12±5.2d
APP/PS1 ischemia	-	12	9.77±0.6a	31.43±9.2a
C57BL ischaemic + aspirin	32	12	1.28±0.4	7.18±3.2
C57BL ischaemic + SLT	32	12	1.14±0.5	5.12±4.4e
APP/PS1 + SLT	32	12	3.38±0.5b	14.38±5.4b
APP/PS1 ischaemic + donepezil hydrochloride	20	12	6.23±0.6c	16.24±6.4c
APP/PS1 ischaemic + SLT	32	12	7.18±0.4c	19.38±6.0c

Notes: ischaemic treatment: both right and left common carotid arteries were separated, and the arterial blood vessel was stimulated with a temperature-controlled current of 80 mu A using an in vivo thrombometer to cause thrombosis. The APP/PS1 ischaemic + donepezil hydrochloride group were administered intragastrically with 20 mg·kg^-1·d^-1 of donepezil hydrochloride. The C57BL ischaemic + aspirin group were administered intragastrically with 32 mg·kg^-1·d^-1 of aspirin, the SLT group were administered intragastrically with 32 mg·kg^-1·d^-1 of SLT and the control group were given 32 mg·kg^-1·d^-1 of solvent. Duration: two months. SLT: Sailuotong; APP: amyloid precursor protein; PS1: presenilin-1. One-way analysis of variance was employed to make comparisons among groups, and in the case of the normal distribution, Tukey’s post hoc test was conducted; otherwise, the Kruskal-Wallis test was adopted. Compared with C57 sham-operated group, ^aP < 0.01, ^dP < 0.05; compared with APP/PS1 ischemia group, ^bP < 0.05, ^cP < 0.01; compared with C57 ischemia group, ^eP < 0.05.